Laroche Daniel, Nkrumah Gideon, Ng Chester
Department of Ophthalmology, New York Eye and Ear of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Ophthalmology, Advance Eyecare of New York, New York, NY, USA.
Middle East Afr J Ophthalmol. 2020 Jan 29;26(4):229-234. doi: 10.4103/meajo.MEAJO_126_19. eCollection 2019 Oct-Dec.
The aim of this study was to determine the postoperative course after the ab interno XEN45 Gel Stent implantation in Black and Afro-Latino, patients with glaucoma.
This was a single-center, retrospective study. All patients with glaucoma who underwent ab interno XEN implantation were included in the study. All of the patients were Black and Afro-Latino making up the demographics of the local community. Investigated parameters were intraocular pressure (IOP), the number of medications, visual acuity, IOP-follow-up, intraoperative and postoperative complications, and additionally performed surgeries.
Of 20 eyes that had undergone the procedure with 1-year follow-up, eight failed before 12 months requiring additional glaucoma surgery. Of the 12 that were successful at 1 year, 9 (75%) eyes underwent XEN + cataract surgery and 3 (25%) had XEN surgery alone. Of the eyes that completed 12-month follow-up, the mean medicated IOP was 15.3 ± 6.2 mmHg at baseline, and 12.9 ± 4.5 mmHg at 12 months, a 16% IOP reduction. Mean medications dropped from 3.58 ± 0.7 preoperatively to 1.75 ± 1.5 at 12 months.
The ab interno XEN gel implant as a standalone procedure or combined with cataract surgery demonstrated a safe and sustained IOP reduction for only 60% of patients after 12 months. In Black and Afro-Latino patients receiving the ab interno XEN implant, 40% of patients needed additional surgery within 12 months.
本研究旨在确定黑人及拉丁裔青光眼患者行内路XEN45凝胶支架植入术后的病程。
这是一项单中心回顾性研究。所有接受内路XEN植入术的青光眼患者均纳入研究。所有患者均为黑人及拉丁裔，构成了当地社区的人口统计学特征。研究参数包括眼压（IOP）、用药数量、视力、眼压随访情况、术中及术后并发症，以及额外进行的手术。
在接受该手术且随访1年的20只眼中，8只在12个月前失败，需要额外进行青光眼手术。在1年后成功的12只眼中，9只（75%）眼接受了XEN + 白内障手术，3只（25%）仅接受了XEN手术。在完成12个月随访的眼中，基线时平均药物治疗眼压为15.3±6.2 mmHg，12个月时为12.9±4.5 mmHg，眼压降低了16%。平均用药量从术前的3.58±0.7降至12个月时的1.75±1.5。
内路XEN凝胶植入术作为单独手术或与白内障手术联合，在12个月后仅60%的患者中显示出安全且持续的眼压降低。在接受内路XEN植入术的黑人和拉丁裔患者中，40%的患者在12个月内需要额外手术。
